The genesis of NETRI.
Based on 10 years of academic research, NETRI was founded in June 2018 in Lyon at the heart of the Gerland biodistrict. Since 2018, NETRI has developed a unique value proposition on the organs-on-chip market. NETRI solutions offer to generate the level of data (throughput) and biological complexity (relevance) required to validate the predictive nature of compounds in humans, with 3 main areas of differentiation:
- High-throughput & interoperable devices : compartmentalization, pump-free and compatible with laboratory equipment.
- Using neurons as a bio-digital sensors : digital transcription of the functional impact (determination of toxicity or efficacy) of products tested on an innervated target organ, creating a digital signature for each compound tested.
- Digital library : comparison of the digital signatures of the compound to be tested with those of compounds already on the market or which have failed in the clinical phase (prediction of toxicity and efficacy).
Previous
Next